Autopsy report · NCT04083898

Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

“Decision made to not move forward with Phase II portion of trial”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 3 years 11 months before it stopped.
• 15 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Washington University School of Medicine

Sponsor type

University, hospital or other

Conditions

Multiple Myeloma

Interventions

Isatuximab; Bendamustine; Prednisone

Participants

15

Sites

1

Countries

United States

Trials that died the same way

• Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
  “Trial did not move to Phase II portion due to poor tolerance of treatment” (79% match in meaning)
• A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
  “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.” (71% match in meaning)
• Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
  “Company decision to discontinue trial” (71% match in meaning)
• A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients.
  “A change in marketing strategy resulted in a decision to not complete the trial.” (70% match in meaning)
• One Touch® Verio®IQ European Clinical Outcomes Study
  “Business decision to withdraw trial” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.